Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxis

被引:110
作者
Fessler, BJ [1 ]
机构
[1] Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA
来源
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY | 2002年 / 16卷 / 02期
关键词
systemic lupus erythematosus; infection; hepatitis; HIV; tuberculosis; herpes zoster; vaccination;
D O I
10.1053/berh.2001.0226
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Infections are one of the leading causes of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Therapeutic, disease-related and genetic factors all contribute to a lupus patient's increased susceptibility to infections. Although bacterial pathogens are the most common cause of infections, a wide variety of pathogens have been reported. In high-risk populations, identification and treatment of chronic infections such as tuberculosis, hepatitis B or human immunodeficiency virus, are important prior to the institution of immunosuppression to prevent reactivation or exacerbation of the infection. judicious use of corticosteroids and cytotoxic drugs is critical in limiting infectious complications. Vaccines against influenza and pneumococcus appear to be safe and immunogenic in SLE patients and their routine administration should be encouraged.
引用
收藏
页码:281 / 291
页数:11
相关论文
共 79 条
[1]  
Abu-Shakra M, 2000, J RHEUMATOL, V27, P1681
[2]  
Albero MD, 1996, NEPHROL DIAL TRANSPL, V11, P1342
[3]  
Alonso CM, 2000, CLIN EXP RHEUMATOL, V18, P510
[4]  
[Anonymous], 2000, MORBIDITY MORTALITY, V49, P1
[5]  
AREND SM, 1995, NEPHROL DIAL TRANSPL, V10, P884
[6]   Vaccination of the immunosuppressed adult patient with rheumatologic disease [J].
Avery, RK .
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 1999, 25 (03) :567-+
[7]  
AYVAZIAN LF, 1948, NEW ENGL J MED, V88, P833
[8]  
Balakrishnan C, 1998, J Assoc Physicians India, V46, P682
[9]  
Bartholomew W R, 1990, Immunol Ser, V52, P33
[10]  
Battafarano DF, 1998, ARTHRITIS RHEUM, V41, P1828, DOI 10.1002/1529-0131(199810)41:10<1828::AID-ART15>3.3.CO